Registration for a live webinar on 'Innovations in antibiotic discovery: combating resistant infections' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
-
1. Priming of T cell responses 1
- Prof. Victor Appay
- Dr. Francesco Nicoli
-
2. Priming of T cell responses 2
- Prof. Victor Appay
- Dr. Francesco Nicoli
-
3. Human tumor antigens as therapeutic targets of cancer
- Prof. Ben Seon
-
4. Myeloid-derived suppressor cells in cancer
- Prof. Dmitry Gabrilovich
-
6. Human NK cells
- Prof. Lorenzo Moretta
- Immune Checkpoint Blockade
-
7. Immune checkpoint blockade in melanoma
- Dr. Elizabeth Buchbinder
-
8. Immunotherapy and radiation for head and neck cancers
- Dr. Jonathan Schoenfeld
-
11. Immune checkpoint blockade in CNS tumors
- Dr. Md. David A. Reardon
-
12. Making cures more common in kidney cancer
- Prof. David McDermott
-
13. Immunotherapy of hepatocellular carcinoma
- Prof. Tim Greten
- Oncolytic Viruses and Cancer Vaccines
-
14. Cancer vaccines 1
- Prof. Cornelis Melief
-
15. Cancer vaccines 2
- Prof. Cornelis Melief
-
16. Gene therapy and virotherapy in the treatment of cancer
- Prof. Leonard Seymour
-
17. Talimogene laherparepvec: first-in-class oncolytic immunotherapy
- Prof. Kevin Harrington
- Archived Lectures *These may not cover the latest advances in the field
-
18. Immunotherapy of hepatocellular carcinoma
- Prof. Tim Greten
-
19. Immune checkpoint blockade and head and neck cancer
- Dr. Jonathan Schoenfeld
-
20. Immune checkpoint blockade in renal cell carcinoma
- Prof. David McDermott
-
21. Immunosuppressive mechanisms in myeloid cells
- Prof. Dmitry Gabrilovich
Printable Handouts
Navigable Slide Index
- Introduction
- Tumor microenvironment
- Naïve T cells can infiltrate tumors (1)
- Naïve T cells can infiltrate tumors (2)
- Tertiary lymphoid structures in cancer
- Neoantigens from mutations
- Immunosuppressive features
- Cancer immunotherapy
- Interaction between cancer and immune system
- Tumor associated antigens
- Vaccines (1)
- Adoptive cell transfer (1)
- Adoptive cell transfer (2)
- Immune checkpoint blockers
- Vaccines (2)
- Immune aging
- Advanced age and malignant diseases
- T cell priming & immuno-surveillance of tumors
- Naïve T cell compartment in the elderly
- in vitro model of naïve CD8+ T cell priming
- in vitro model-experimental procedure
- in vitro model-advantages
- CD8+ T cell priming efficacy in the elderly
- Adjuvant and high quality CD8+ T cells
- Summary slide
Topics Covered
- T cell priming
- Modulation of T cell priming
- Tumor microenvironment
- Cancer immunotherapy
- Immune aging
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Appay, V. and Nicoli, F. (2017, November 30). Priming of T cell responses 2 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved May 6, 2025, from https://doi.org/10.69645/PHCJ9694.Export Citation (RIS)
Publication History
- Published on November 30, 2017
Financial Disclosures
- Prof. Victor Appay has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
- Dr. Francesco Nicoli has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Priming of T cell responses 2
Published on November 30, 2017
19 min
A selection of talks on Cancer
Transcript
Please wait while the transcript is being prepared...
0:00
Hi, this is Victor Appay speaking from
The National Institute of Health and Medical Research in France.
In the second part of my talk,
I will concentrate more on the relationship of
T cell priming in the context of tumour micro-environment,
and its application in the context of cancer immunotherapy and aging.
0:20
Now in this fourth part,
I will discuss about T cell priming in the context of the tumour micro-environment.
0:29
It has been shown that upon injection in mice,
naive cells can infiltrate directly tumours,
and this has been associated with an improved survival of the mice bearing the tumours.
0:45
Interestingly, increasing evidence support that tumours can support
the infiltration, activation, and effector differentiation of naive CD8 T cells.
Indeed, the adoptive transfer of naive tumour-specific CD8 T cells,
into tumour-bearing mice, has been associated with
the accumulation of activated CD8 T cells in the tumours,
the acquisition of effector function,
and the presentation of antigen to
these cells by cross-presenting antigen presenting cells.
Also, the recruitment of naive T cell within tumours has been shown to be
favoured by the presence of high endothelial venules or HEVs.
HEVs have been identified in a range of human tumours,
and usually their presence has been associated with
the observation of CD8 T effector cells, B cells,
Th1 cells within the tumours,
and organised into so-called tertiary lymphoid structures or TLS.